Stratec SE SBS.DE XETRA · Healthcare · Germany
27.85 € +4.11% +1.10 €
Summary
41 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 11 EUR is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 3.0% a year over the last 3 years.
- It missed profit estimates 6 times in the last 8 quarters.
- Operating profit covers the interest on its debt only 2.0 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 0.1% a year over 5 years. Over the last 3 years it fell by 3.0% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of 42.4M €.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.22%
- Raised in a row
- 1 year
You receive 0.60 € per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail